Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

Cancer Gene Therapy

Volumn 10, Issue 10, 2003, Pages 737-744

  Nemunaitis, John ^a,b,c,f   Cunningham, Casey ^a,b,c   Senzer, Neil ^a,b,c   Kuhn, Joseph ^b,c   Cramm, Jennifer ^a   Litz, Craig ^e   Cavagnolo, Robert ^e   Cahill, Ann ^d   Clairmont, Caroline ^d   Sznol, Mario ^d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Mary Crowley Medical Research Center   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Vion Pharmaceuticals Incorporated   (United States)

^e St Paul University Hospital   (United States)

^f Collins Bldg ^*  (United States)

Author keywords

5 fluorouracil; Cytosine deaminase; Salmonella

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CORONARY ARTERY SPASM; DNA MODIFICATION; ESCHERICHIA COLI; ESOPHAGUS CARCINOMA; FEMALE; FEVER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HEAD AND NECK CARCINOMA; HUMAN; INSOMNIA; MALE; MUSCLE WEAKNESS; PAIN; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SALMONELLA;

AGED; AGED, 80 AND OVER; CYTOSINE DEAMINASE; ESCHERICHIA COLI; FEMALE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; HEAD; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NECK; NEOPLASMS; PILOT PROJECTS; SALMONELLA;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; SALMONELLA;

EID: 12444302834     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700634     Document Type: Article

References (39)

1. Mose JR, Mose G. Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich Tumor des Maus. Z Krebsforsch. 1959;63:63-74.
2. Mose JR, Mose G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 1964;24:212-216.
3. Thiele EH, Arison R, Boxer GE. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res. 1964;2:222-233.
4. Engelbart K, Gericke D. Oncolysis by clostridia V. Transplanted tumors of the hamster. Cancer Res. 1954;24:239-243.
5. Carey RW, Holland JF, Whang HY, et al. Clostridial oncolysis in man. Eur J Cancer. 1967;3:37-46.
6. Heppner F, Mose J. The liquefaction (oncolysis) of malignant gliomas by a non-pathogenic clostridium. Acta Neurol. 1978;12:123-125.
7. Heppner F, Mose J, Ascher PW, Walter G. Oncolysis of malignant gliomas of the brain. The 13th International Congress on Chemotherapy, 1983: vol 226, 38-45.
8. Giel CP. Abscess formation in pheochromocytoma. N Engl J Med. 1954;251:980-982.
9. Simmers TA, Mijnhout G, Van Meyel JJ. Salmonellosis: an usual complication of hepatocellular carcinoma. Scand J Gastroenterol. 1997;32:1180-1182.
10. Noguerado A, Cabanyes J, Vivancos J, et al. Abscess caused by Salmonella enteritidis within a glioblastoma multiforme. J Infect. 1987;15:61-63.
11. Black PH, Kunz LJ, Swartz MN. Salmonellosis: a review of some unusual aspects. N Engl J Med. 1960;262:921-926.
12. Rodriguez RE, Valero V, Watanakunakom C. Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an usual case. Rev Infect Dis. 1986;8:31-41.
13. Grahm FO, Coleman PN. Infection of a secondary carcinoma by Salmonella montevideo. BMJ. 1952;1:1116.
14. Luo X, Ittensohn M, Liu Y, et al. Genetically modified Sahnonella typhimurium inhibited growth of primary tumors and metastases. Proc Am Assoc Cancer Res. 1999;40:87.
15. Low K, Ittensohn M, Lin S, et al. VNP20009, a genetically modified Salmonella typhimurium for treatment of solid tumors. Proc Am Assoc Cancer Res. 1999;40:87.
16. Low KB, Ittensohn M, Le T, et al. Lipid A mutant salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol. 1999;17:37-41.
17. Pawelek JM, Low KB, Bermudes D. Tumor-targeted salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537-4544.
18. Khan SA, Everest P, Servos S. A lethal role for lipid A in salmonella infection. Mol Microbiol. 1998;29:571-579.
19. Lee KC, Zheng LM, Margitich D, Almassian B, King I. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain. TAPET-CD, being developed as an anti-tumor agent. Int J Toxicol. 2001;20:207-217.
20. Zheng LM, Luo X, Feng M, et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oucol Res. 2000;12:127-135.
21. Luo X, Li Z, Lin S, et al. Anti-tumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res. 2002;12:501-508.
22. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20:142-152.
23. Dinarello CA. Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. Chest. 1997;112:321S-329S.
24. King I, Bermudes D, Lin S, et al. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum Gene Ther. 2002;13:1225-1233.
25. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Therapy. 1995;2:235-244.
26. Haskell CM, Fluorouracil. In: In Cancer Treatment. WB Sounds Company. 1995:116-119.
27. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 1993;43:380-387.
28. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy. 2002;9:291-296.
29. Donnenburg MS, Kaper JB. Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector. Infect Immunity. 1991;59:4310-4317.
30. Platt J, Sodi S, Kelly M, et al. Antitumor effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer. 2000;36:2397-2402.
31. Khil MS, Kim JH, Mullen CA, et al. Radiosensitization of 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin Cancer Res. 1996;2:53-57.
32. Gabel M, Kim JH, Kolozsvary A, et al. Selective in vivo radiosensitization by 5-fluorouracil of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase gene. Int J Radiat Oncol Biol Phys. 1998;41:883-887.
33. Lawrence TS, Rehemtulla A, Ng EY. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res. 1998;58:2588-2593.
34. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves and efficient memory. J Immunol. 1995;154:5302-5312.
35. Pierrefite-Carle V, Baque P, Gavelli A, et al. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst. 1999;91:2014-2019.
36. Hermiston T. Fighting fire with fire: attacking the complexity of human tumors with armed therapeutic viruses. Curr Opin Mol Ther. 2002;4:334-342.
37. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol. 2001;38:177-192.
38. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol. 2001;187:22-36.
39. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997;8:985-1001.